Zoetis Inc. (NYSE:ZTS) Shares Purchased by Chapman Investment Management LLC

by · The Cerbat Gem

Chapman Investment Management LLC raised its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 1.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 21,210 shares of the company’s stock after buying an additional 235 shares during the period. Zoetis comprises about 3.0% of Chapman Investment Management LLC’s portfolio, making the stock its 13th largest holding. Chapman Investment Management LLC’s holdings in Zoetis were worth $4,144,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZTS. Prevail Innovative Wealth Advisors LLC raised its position in shares of Zoetis by 24.5% in the first quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after buying an additional 3,738 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in Zoetis by 58.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock valued at $7,095,000 after acquiring an additional 15,491 shares during the last quarter. Duality Advisers LP lifted its stake in Zoetis by 43.7% in the 1st quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock worth $6,877,000 after purchasing an additional 12,359 shares in the last quarter. M&G Plc acquired a new position in shares of Zoetis during the 1st quarter worth approximately $19,819,000. Finally, Cetera Investment Advisers grew its position in shares of Zoetis by 275.2% in the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after purchasing an additional 70,476 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $221.44.

Read Our Latest Report on Zoetis

Zoetis Stock Up 1.8 %

Shares of NYSE ZTS opened at $181.95 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The business’s 50 day moving average is $188.97 and its two-hundred day moving average is $178.51. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The firm has a market cap of $82.43 billion, a price-to-earnings ratio of 35.61, a PEG ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.41 EPS. Research analysts predict that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.66%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More